TransMedics Group, Inc. TMDX, in a strategic move to revolutionize organ transplant therapy, has successfully concluded the acquisition of Summit Aviation, a premier U.S. charter flight operator. The acquisition marks a pivotal step forward for TransMedics, positioning it as a leading player in the realm of organ transplantation logistics.
The financial terms of the deal, however, remained undisclosed.
Introducing TransMedics Aviation
TransMedics' acquisition of Summit Aviation sets the stage for the establishment of TransMedics Aviation, a pioneering endeavor that will serve as the first integrated national provider of air logistics dedicated exclusively to organ transplantation within the United States. This latest step signifies TransMedics' dedication to enhancing the reach and coverage of the National OCS Program.
The acquisition is hailed as a cornerstone of TransMedics' overarching strategy, seamlessly aligning Summit Aviation's advanced air charter services and strong team culture with TransMedics' globally recognized clinical expertise and cutting-edge transplant technology. This alignment positions TransMedics to not only maintain but elevate its reputation for providing world-class clinical services and state-of-the-art transplant solutions.
Ben Walton, founder and president of Summit Aviation, expressed excitement about the partnership, highlighting the collective ability to revolutionize transplant aviation. The union of TransMedics' groundbreaking Organ Care System and Summit Aviation's aviation prowess promises to reshape organ transportation, ultimately saving more lives.
Image Source: Zacks Investment Research
The global organ transport devices market holds promise. A Future Market Insights report revealed its value at approximately $105.9 million in 2021 stated that it has a projected CAGR of 8.7% from 2022 to 2032.
Technological advancements have elevated healthcare services and quality, particularly in organ transplantation. As demand for organ transplants rises, increased investments and research in new organ care products are expected to drive the market's growth, indicating a brighter future for improved organ transportation methods.
Share Price Performance
In the past year, TMDX shares have risen 45.8% against the industry’s decline of 3.8%.
Zacks Rank and Key Picks
TransMedics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Penumbra, Inc. PEN, Integer Holdings Corporation ITGR and Patterson Companies, Inc. PDCO.
Penumbra, carrying a Zacks Rank of 1 (Strong Buy), reported second-quarter 2023 adjusted earnings per share (EPS) of 43 cents, beating the Zacks Consensus Estimate by 53.6%. Revenues of $261.5 million outpaced the consensus mark by 3.3%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Penumbra has an estimated growth rate of 57.9% for 2024. PEN’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 94.2%.
Patterson Companies sports a Zacks Rank of 1. PDCO has an estimated long-term growth rate of 9.2%.
Patterson Companies’ earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 4.5%.
Integer Holdings reported second-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 15.2%. Revenues of $400 million surpassed the Zacks Consensus Estimate by 8.9%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 12.1%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 8.4%.
Disclaimer: This article has been written with the assistance of Generative AI. However, the author has reviewed, revised, supplemented, and rewritten parts of this content to ensure its originality and the precision of the incorporated information.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report